The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure

The present review includes data on efficacy and safety of pomalidomide, an immunomodulating 3rd generation drug used for treatment of relapsed and refractory multiple myeloma patients with renal failure. The results of multicenter randomized trials proved similar efficacy and comparable safety prof...

Full description

Saved in:
Bibliographic Details
Main Authors: IG Rekhtina, MV Nareiko, LP Mendeleeva
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2018-10-01
Series:Клиническая онкогематология
Subjects:
Online Access:http://bloodjournal.ru/wp-content/uploads/2018/09/1-1.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850246954469031936
author IG Rekhtina
MV Nareiko
LP Mendeleeva
author_facet IG Rekhtina
MV Nareiko
LP Mendeleeva
author_sort IG Rekhtina
collection DOAJ
description The present review includes data on efficacy and safety of pomalidomide, an immunomodulating 3rd generation drug used for treatment of relapsed and refractory multiple myeloma patients with renal failure. The results of multicenter randomized trials proved similar efficacy and comparable safety profile in patients with normal renal function and patients with moderate and/or severe renal failure. All patients received the standard starting dose. Pomalidomide dose needs to be reduced in response to hematological toxicity. The paper provides practical guidelines on the use of pomalidomide and treatment of adverse events adopted by consensus of international experts. Current approaches to multiple myeloma with renal failure, and the use of pomalidomide in particular, are demonstrated by means of a clinical case.
format Article
id doaj-art-143cf34edc5942a08a9ff47ce4bd76b8
institution OA Journals
issn 1997-6933
2500-2139
language Russian
publishDate 2018-10-01
publisher Practical Medicine Publishing House
record_format Article
series Клиническая онкогематология
spelling doaj-art-143cf34edc5942a08a9ff47ce4bd76b82025-08-20T01:59:04ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392018-10-0111428328710.21320/2500-2139-2018-11-4-283-287The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal FailureIG Rekhtina0MV Nareiko1 LP Mendeleeva2National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167The present review includes data on efficacy and safety of pomalidomide, an immunomodulating 3rd generation drug used for treatment of relapsed and refractory multiple myeloma patients with renal failure. The results of multicenter randomized trials proved similar efficacy and comparable safety profile in patients with normal renal function and patients with moderate and/or severe renal failure. All patients received the standard starting dose. Pomalidomide dose needs to be reduced in response to hematological toxicity. The paper provides practical guidelines on the use of pomalidomide and treatment of adverse events adopted by consensus of international experts. Current approaches to multiple myeloma with renal failure, and the use of pomalidomide in particular, are demonstrated by means of a clinical case.http://bloodjournal.ru/wp-content/uploads/2018/09/1-1.pdfpomalidomidemultiple myelomarenal failure
spellingShingle IG Rekhtina
MV Nareiko
LP Mendeleeva
The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
Клиническая онкогематология
pomalidomide
multiple myeloma
renal failure
title The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
title_full The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
title_fullStr The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
title_full_unstemmed The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
title_short The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
title_sort use of pomalidomide in the treatment of relapsed refractory multiple myeloma in patients with renal failure
topic pomalidomide
multiple myeloma
renal failure
url http://bloodjournal.ru/wp-content/uploads/2018/09/1-1.pdf
work_keys_str_mv AT igrekhtina theuseofpomalidomideinthetreatmentofrelapsedrefractorymultiplemyelomainpatientswithrenalfailure
AT mvnareiko theuseofpomalidomideinthetreatmentofrelapsedrefractorymultiplemyelomainpatientswithrenalfailure
AT lpmendeleeva theuseofpomalidomideinthetreatmentofrelapsedrefractorymultiplemyelomainpatientswithrenalfailure
AT igrekhtina useofpomalidomideinthetreatmentofrelapsedrefractorymultiplemyelomainpatientswithrenalfailure
AT mvnareiko useofpomalidomideinthetreatmentofrelapsedrefractorymultiplemyelomainpatientswithrenalfailure
AT lpmendeleeva useofpomalidomideinthetreatmentofrelapsedrefractorymultiplemyelomainpatientswithrenalfailure